Abstract 1887P
Background
Palliative care patients experience chronic sorrow due to living loss such as impairment in bodily functions, inability to carry out daily life, and meaninglessness due to impending death. Logotherapy was shown to be an effective method to cope with end-of-life related distress. The aim of this study was to investigate effectiveness of logotherapy on chronic sorrow, dignity, and meaning in life on palliative care patients.
Methods
This randomized-controlled study was conducted between September 2021-June 2023 in medical and gynecological oncology clinics of a university hospital, with 58 adult advanced cancer patients requiring palliative care. Participants were assigned to either intervention (n=29) or control (n=29) group by simple randomization via a computer program. Participants, ≥18 years old, having advanced solid cancer, aware of their diagnosis, having no communication problem or mental disorder, with a life expectancy over 6 months and Palliative Performance Scale score ≥%50, and verbally expressing to experience chronic sorrow were included. Data were collected with demographic form, Patient Dignity Inventory (PDI), Prolonged Grief Disorder Scale-Patient Form (PGD-PF), presence of meaning (MIL-PM) and search for meaning (MIL-SM) subdimensions of Meaning in Life (MIL) Questionnaire. Data were collected on admission, at the 4th and 8th weeks. Intervention group received logotherapy, lasting about of 45 minutes, 2 days a week for 4 weeks. Control group received routine care.
Results
The mean scores of PDI (p=0.01), PGD-PF (p=0.01) and MIL-SM (p=0.11) were lower in the intervention group, while MIL-PM was higher (p=0.02). Within group analysis showed a decrease in PDI (p<0.01), PGD-PF (p=0.01), MIL-SM (p=0.02), and increase in MIL-PM (p<0.01) in the intervention group while mean scores of PDI (p=0.01), PGD-PF (p=0.01), MIL-SM (p=0.04), and MIL-PM (p=0.05) decreased in control group.
Conclusions
Logotherapy was found effective on decreasing sorrow and dignity related distress of palliative care patients, while increasing finding meaning in life.
Clinical trial identification
NCT05129059.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12